We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


RNAi Screening of Rat Druggable Genes Using Sirna Design

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

QIAGEN has launched the Rat Druggable Genome siRNA Set V1.0. This set can enable potent and specific knockdown of approximately 6000 rat genes which correspond to human genes of therapeutic value.

The company has designed these siRNAs using HP OnGuard siRNA Design which incorporates a neural-network, proprietary homology analysis, and advanced design features based on the knowledge about the mechanism of RNAi. Subsets targeting 426 GPCR genes, 738 kinase genes, or 198 phosphatase genes are also available.

HP OnGuard siRNA Design includes an artificial neural-network for selection of highly potent siRNAs and stringent homology analysis to ensure specificity.

Additional features include design of siRNAs to target the sequences from NCBI, 3' UTR/seed region analysis, SNP avoidance, and interferon motif avoidance.

siRNA design is reinforced using the results from QIAGEN’s validation project in which thousands of siRNAs have been tested for effectiveness by real-time RT-PCR. Data from Affymetrix GeneChip analysis is used to minimize the potential for off-target effects.

The Rat Druggable Genome siRNA Set V1.0 is provided in flexible scales and formats to suit specific screening requirements. siRNAs are provided as individual siRNAs or pools for maximum flexibility.